Characteristics of CLL patients according to the IgVH mutational status
| . | All patients . | Somatically mutated . | Somatically unmutated . | P . |
|---|---|---|---|---|
| No. of cases (%) | 82 | 49 (59.8) | 33 (40.2) | NA |
| Mean age, y | 69 | 68 | 71 | NA |
| Sex, M/F | 49/33 | 30/19 | 19/14 | NA |
| Mean duration of follow-up, mo | 92.1 | 98.5 | 82.4 | NA |
| Risk status | .1773-153 | |||
| Low risk3-150(%) | 59/82 (72.0) | 39/49 (79.6) | 20/33 (60.6) | |
| Intermediate risk3-150(%) | 18/82 (22.0) | 8/49 (16.3) | 10/33 (30.3) | |
| High risk3-150 (%) | 5/82 (6.1) | 2/49 (4.1) | 3/33 (9.1) | |
| Disease status | <.0013-153 | |||
| Stable disease (%) | 48/82 (58.5) | 38/49 (77.6) | 10/33 (30.3) | |
| Progressive disease (%) | 34/82 (41.5) | 11/49 (22.4) | 23/33 (69.7) | |
| Autoimmune manifestations (%) | 15/82 (18.3) | 6/15 (40.0) | 9/15 (60.0) | .0773-153 |
| Treatment | ||||
| Not requiring treatment (%) | 39/82 (47.6) | 30/49 (61.2) | 9/33 (27.3) | .0023-153 |
| Requiring treatment (%) | 43/82 (52.4) | 19/49 (38.8) | 24/33 (72.7) | |
| Blood parameters | ||||
| Mean β2-microglobulin count, mg/L3-151 | 3.0 | 2.3 | 3.9 | .0023-155 |
| Mean Hb count, g/dL | 12.8 | 13.4 | 11.9 | <.0013-155 |
| Mean lymphocyte count, per μL | 43 700 | 29 800 | 64 300 | <.0013-155 |
| LDT, %3-152 | 121.5 | 58.1 | 215.6 | .0143-155 |
| . | All patients . | Somatically mutated . | Somatically unmutated . | P . |
|---|---|---|---|---|
| No. of cases (%) | 82 | 49 (59.8) | 33 (40.2) | NA |
| Mean age, y | 69 | 68 | 71 | NA |
| Sex, M/F | 49/33 | 30/19 | 19/14 | NA |
| Mean duration of follow-up, mo | 92.1 | 98.5 | 82.4 | NA |
| Risk status | .1773-153 | |||
| Low risk3-150(%) | 59/82 (72.0) | 39/49 (79.6) | 20/33 (60.6) | |
| Intermediate risk3-150(%) | 18/82 (22.0) | 8/49 (16.3) | 10/33 (30.3) | |
| High risk3-150 (%) | 5/82 (6.1) | 2/49 (4.1) | 3/33 (9.1) | |
| Disease status | <.0013-153 | |||
| Stable disease (%) | 48/82 (58.5) | 38/49 (77.6) | 10/33 (30.3) | |
| Progressive disease (%) | 34/82 (41.5) | 11/49 (22.4) | 23/33 (69.7) | |
| Autoimmune manifestations (%) | 15/82 (18.3) | 6/15 (40.0) | 9/15 (60.0) | .0773-153 |
| Treatment | ||||
| Not requiring treatment (%) | 39/82 (47.6) | 30/49 (61.2) | 9/33 (27.3) | .0023-153 |
| Requiring treatment (%) | 43/82 (52.4) | 19/49 (38.8) | 24/33 (72.7) | |
| Blood parameters | ||||
| Mean β2-microglobulin count, mg/L3-151 | 3.0 | 2.3 | 3.9 | .0023-155 |
| Mean Hb count, g/dL | 12.8 | 13.4 | 11.9 | <.0013-155 |
| Mean lymphocyte count, per μL | 43 700 | 29 800 | 64 300 | <.0013-155 |
| LDT, %3-152 | 121.5 | 58.1 | 215.6 | .0143-155 |
Rai modified stage at diagnosis.
β2-microglobulin serum count was obtained in 63 patients.
Lymphocyte doubling time (as increasing percent in 6 months).
P for the comparison among mutated and unmutated subgroups was calculated using the χ2 test.
P refers to 1-way ANOVA test.